Managing patients with myelofibrosis (MF)-either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia-presents many challenges to the hematologist. MF patients suffer from a range of debilitating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and transformation to a treatment-refractory blast phase). Cure is potentially achievable through allogeneic stem cell transplantation; however, this therapy is either inappropriate or not feasible for the majority of patients.
Splenomegaly in Myelofibrosis: A Hematologist's Challenge
Myelofibrosis (MF) includes primary myelofibrosis (PMF) and MF that has arisen from an antecedent polycythemia vera (PV) or essential thrombocythemia (ET) (post PV/ET MF).
1 MF can affect patients in various ways, including progressive splenomegaly, cytopenias (particularly anemia), and troublesome constitutional symptoms (i.e., night sweats, fevers, unintentional weight loss, debilitating fatigue). 2 MF can also result in blastic transformation 3 and death. 4 Splenomegaly can be a major independent source of morbidity and detriment to quality of life when it develops in MF patients. 5, 6 First, splenomegaly (sometimes massive [>10 kg]) can lead to pain, early satiety, bloating or even portal hypertension. How do I manage the myelosuppression brought about by medical therapy? Which patients should be considered for splenectomy or splenic radiation? What is the impact of experimental drugs (particularly the JAK2 inhibitors) on splenomegaly, and would my patient benefit from treatment with one of these agents? These are the key challenges for hematologists involved in treating patients with MF (they also comprise a large
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MF Management Strategies: Prognosis and Treatment Goals
Deciding on a treatment plan for patients with MF requires both an assessment of the disease impact at diagnosis and an accurate assessment of prognosis. The
International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)
recently published an International Prognostic Scoring System (IPSS-MF) (Table 1) to aid in assessing MF prognosis. The IPSS-MF defines 4 risk groups with projected survival medians for each group ranging from a median of 27 months for high risk to 135 months for low risk disease. 8 Currently, there is only 1 curative therapy for MF-allogeneic stem cell transplantation, which offers a 58% 3-year survival rate with a 32% relapse-free mortality rate. 9 More favorable outcomes have been reported with reduced-intensity transplantation (85% survival rate at a median of 31 months), but long-term outcomes (including burden of chronic graft-versus-host disease) need to be assessed. 10 Therefore, the key question after MF diagnosis is whether the patient is a suitable candidate for allogeneic transplantation (Figure 1 ). Given that no other therapy has been found curative or has been proved to confer a survival advantage in MF, all other non-transplantation forms of therapy must be considered palliative in nature and intent.
Which Patients With MF Require Treatment for Splenomegaly?
The first decision made in managing splenomegaly in MF patients is whether the patient has sufficient symptoms (i.e., pain, mechanical symptoms, splenic infarcts, or refractory cytopenias) (Figure 1 ) to merit therapy. Splenomegaly and cytopenias are
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From sometimes present concurrently (i.e., splenic sequestration exacerbates ineffective hematopoiesis from the marrow). Frequently, however, splenomegaly may exist with adequate peripheral blood counts in those patients whose marrow remains very proliferative. The presence or absence of concurrent cytopenias is essential in the decision-making process because many therapies have a detrimental impact on any cytopenias present. Non-transplant (i.e., palliative) therapeutic options are judged by their efficacy in achieving symptom relief balanced against toxicity. Assessing the patient's performance status and peripheral blood counts to determine the ability to tolerate the potential myelosuppression of medical therapy is central in therapy selection (Figure 1 ).
Medical Therapy for Splenomegaly in MF
Medical therapy is the cornerstone therapeutic option for symptomatic splenomegaly in patients with MF (Table 2 ). In MF, sequestration of immature circulating myeloid progenitors leads to accumulation and proliferation in the splenic cords. 20 Current medical therapies can ameliorate splenomegaly in MF mainly through nonspecific myelosuppression, thereby decreasing the immature circulating myeloid pool accumulating in the spleen.
When considering current medical therapies for splenomegaly in MF patients, I
categorize them into 2 distinct tiers: Tier 1 consists predominantly of oral agents with (usually) modest toxicity; tier 2 includes more aggressive approaches suitable for patients with severe splenomegaly or involvement of other organs by extramedullary hematopoiesis (EMH) (i.e., lungs, abdominal cavity, pericardium etc.). In those patients, a more intensive, frequently parenteral (intravenous or subcutaneous), myelosuppressive approach may be warranted. The choice of both initial and subsequent therapies should be based on toxicity profile and specifically the ability to withstand myelosuppression 21 Nevertheless, more modest reductions in splenomegaly may benefit some patients with MF. A second limitation is that splenomegaly, compared to thrombocytosis, is less responsive to hydroxyurea and might require a higher dose (ie, 2-3 grams/day).
Third, hydroxyurea therapy may potentially exacerbate cytopenias, particularly at higher doses. Responses to hydroxyurea for splenomegaly usually occur within 2 to 3 months, and the dose must be titrated to achieve the benefit for splenomegaly by lowering the leukocyte count as best tolerated or to the lower limits of the normal range.
Oral Alkylators
Alkylators such as melphalan and busulfan can alleviate splenomegaly in some MF patients. However, myelosuppression and increased the risk of blastic transformation are potential adverse effects for both medications. In one study, 13 melphalan (2.5 mg orally 3 times per week) reduced spleen size in 66% of patients; however, 26% of the study cohort developed acute leukemia. Busulfan can be used to treat splenomegaly, 22 For personal use only. on April 14, 2017. by guest www.bloodjournal.org From although it was used more classically in the treatment of chronic myeloid leukemia in the pre-imatinib era. 23 
Immunomodulatory Drugs
The immunomodulatory drugs known collectively as IMiDs (i.e. thalidomide, lenalidomide, pomalidomide) inhibit cytokines and have antiangiogenic properties.
IMiDs have been used primarily for palliation in MF patients with cytopenias (anemia and thrombocytopenia) but may also be used to reduce splenomegaly. This combination of potential effects should lead to consideration of IMiD therapy for patients with concurrent cytopenias and splenomegaly.
Thalidomide produced responses for cytopenias in MF patients but was not well tolerated. 24 Low-dose (50 mg/day) thalidomide combined with a prednisone taper (THAL-PRED regimen) 15 achieves significant responses for anemia (67%), thrombocytopenia (75%), and splenomegaly (33%) in MF patients and was better tolerated than single-agent thalidomide. Subsequently, lenalidomide (LEN; a secondgeneration IMiD) was evaluated in 68 patients with symptomatic MF, achieving overall response rates of 22% for anemia, 33% for splenomegaly, and 50% for thrombocytopenia. 25 Lenalidomide was effective in patients where prior treatment with thalidomide had failed and, given its more significant myelosuppressive properties, was better tolerated if patients' pretreatment peripheral blood neutrophil and platelet counts were adequate. Also, as in del(5q) myelodysplastic syndromes, 26 MF patients with an abnormality of chromosome 5 seem to respond best to lenalinomide. 
Interferon-alfa
Therapy with interferon-alfa (IFN-α) has been used in MF patients based on its cytoreductive properties and has been effective in patients with PV. 28 However, clinical trials of IFN-α in MF with both standard preparations 29 and pegylated interferon alpha 
Tier 2

Cladribine
Palliative benefit from the purine nucleoside analog, 2-chlorodeoxyadenosine (2-CdA), has been reported in MF patients. 17 2-CdA has been administered as 4 to 6 oncemonthly cycles of treatment with either 0.1 mg/kg/day intravenously by continuous infusion for 7 days or 5 mg/m 2 intravenously over 2 hours for 5 consecutive days. In the Mayo Clinic experience, we observed responses in 55%, 50%, 55% and 40% of patients for splenomegaly, thrombocytosis, leukocytosis, and anemia, respectively. 17 Responses were frequently durable and lasted for a median of 6 months after discontinuation of treatment. Myelosuppression is the primary toxicity of this regimen, with occasional additional adverse effects of gastrointestinal disturbances. I believe that 2-CdA is the most helpful of the tier 2 agents and should be given on monthly cycles (up to 4 cycles) to achieve maximal response for refractory splenomegaly.
Hypomethylating Agents
The 2 hypomethylating agents approved for myelodysplastic syndromes (MDS), azacytidine (AZA) and decitabine, have been tested in MF patients with a goal of improving cytopenias and splenomegaly or delaying blastic transformation. Recent trials of AZA (75 mg/m 2 /day for 5 or 7 days) 18, 19 showed a 21% response rate for splenomegaly in MF using the 7-day regimen only. 18 The lack of success for the 5-day regimen in the trial leads me to suggest use of only the 7-day regimen at this time.
Decitabine use in MF is in the early stages of testing, and trials are under way. The frequent visits required for administration and myelosuppression, the most common adverse effect, limit the use of these therapies in MF patients.
Low-intensity Therapy for Acute Leukemia
A range of myelosuppressive therapies most typically employed for acute leukemia or higher-risk MDS have been used anecdotally to treat MF patients with refractory splenomegaly. Low-dose subcutaneous cytarabine and daunorubicin administered as a single agent (60 mg/m 2 /day for 3 days) are included in this group.
These strategies, however, have not been vetted through structured clinical trials, and I
only use them in difficult cases in which clinical trial participation is not an option.
Splenectomy
Therapeutic Splenectomy in MF
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The experience with splenectomy in MF patients dates back to the beginning of the 20 th century (Table 3) . 31 Progressive surgical series demonstrated a significant but slowly decreasing (due to improvements in surgical technique, antimicrobials, and patient selection) perioperative mortality rate. Although splenectomy can be helpful for improving symptoms in MF patients, it seems to have no clear effect on patient survival, disease course, or intramedullary manifestations of the disease.
Current Outcomes
We recently analyzed 3 decades of experience with palliative splenectomy in MF at Mayo Clinic 32, 33 to see if better control of postsplenectomy thrombocytosis and modern operative techniques and supportive care have diminished morbidity and mortality.
Patients and outcomes are summarized in Table 2 . 34 Although meaningful improvement in symptoms was observed in 30%-50% of patients, complication rates (27.7% overall, 6.7% fatal) are sobering and indicate that candidates for surgery should be chosen carefully and monitored closely in the perioperative period .
Candidates for Splenectomy
Given the potential dangers of splenectomy, the procedure should be considered only for patients who meet several criteria: substantial and refractory splenic symptoms (ie, requiring narcotics or significantly interfering with quality of life); status as adequate surgical candidates without decompensated coagulopathy or significant comorbidities;
treated unsuccessfully with at least 1 medical therapy for splenomegaly (if eligible and able to enroll into a JAK2 inhibitor trial [see below], this should be considered); have an adequate performance status and life expectancy (i.e., > 1 year) to consider this surgical procedure. I would consider patients meeting the above criteria with refractory cytopenias candidates for splenectomy, but they should be aware that the cytopenias may not improve. Additionally, many of the constitutional symptoms of the disease (i.e., fever, night sweats, and fatigue) are not linked to splenomegaly; therefore, improvement in these symptoms should not be expected. Splenectomy preceding allogeneic stem cell transplant speeds engraftment but without a significant improvement in outcomes; given the risks outlined above, routine pretransplant splenectomy is not recommended.
35
Perioperative Management
The major risk with splenectomy remains perioperative thrombosis and hemorrhage; given that fact, our practice at Mayo Clinic has evolved to aggressively control postoperative platelet counts. Indeed, in our analysis, perioperative thrombohemorrhagic complications decreased in the last decade because we use platelet apheresis as necessary and promptly administer cytoreductive agents to counteract postsplenectomy thrombocytosis. 34 I now use hydroxyurea to treat patients with postoperative platelet counts rising above 300 x 10 9 /L, and plateletpheresis to treat those with counts exceeding 450 x 10 9 /L, within postoperative weeks 1 and 2, although these guidelines have not been vetted by a randomized trial.
Splenic Radiotherapy
Radiotherapy for MF
Radiotherapy has several uses in MF (Table 4) . EMH is exquisitely sensitive to external beam radiotherapy in patients with MF, regardless of location. In patients with MF, the lungs 43 (where EMH can contribute to pulmonary hypertension), paraspinal masses, 6 and spleen are frequently irradiated sites. Splenomegaly can be treated with external beam radiotherapy for palliation, but the benefit is typically transient and myelosuppression can be severe.
Candidates for Splenic Radiotherapy
Splenic radiation is effective for palliating MF-associated splenomegaly, but the effects are transient. Additionally, the abscopal effects of the radiotherapy can lead to significant myelosuppression and profound thrombocytopenia. Splenic radiotherapy is of greatest utility for patients with considerable symptoms and an adequate platelet count who, because of age or comorbidities, would be unlikely to undergo splenectomy in the future.
Reported Outcomes for Splenic Radiotherapy
Several reports (see Table 3 ) have described the palliative benefit of external beam radiotherapy for improving symptomatic splenomegaly in MF. 40, 41 The Mayo Clinic experience 40 included a group of 23 MF patients (who received a total of 49 courses of radiotherapy) who received a median radiation course of 277 cGy in a median of 8 fractions. An objective decrease in spleen size was noted after 94% of radiotherapy courses; however, 44% of patients experienced posttreatment cytopenias (26% were severe; 13% fatal). Splenic radiation also seemed to increase morbidity and mortality of subsequent splenectomy when undertaken. This latter effect seems related to the development of splenic adhesions to the abdominal wall and surrounding viscera, leading to greater complexity with subsequent attempts at surgical extirpation. Additionally, in irradiated areas delayed hemorrhage was common resulting in blunt dissection of the spleen away from other structures.
Experimental Medical Therapy
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JAK2 Inhibitors
The discovery of several key MPD-associated mutations has broadened the therapeutic horizons for MF significantly (Table 5) . 49 Discovery of the JAK2 V617F mutation in the 14 th exon of JAK2 was followed by the 10 mutations currently described in the 12 th exon of JAK2. Additionally, 5 constitutively activating mutations thus far have identified in the thrombopoietin receptor, MPL, which signals through JAK2. All of these mutations seem to feed into a final common pathway of cellular activation through the PI3 kinase pathway, the STAT pathway, and the MAP kinase pathway.
49
The best-studied clinical experience for a JAK2 inhibitor is for INCB018424
(Incyte Co, Wilmington, DE), which is selective against JAK1 and JAK2; this agent leads to significant reduction in splenomegaly and dramatic improvement in constitutional symptoms 44 with toxicities of thrombocytopenia and anemia 44 (Table 5) . Additionally, the adverse increase in inflammatory cytokines observed in myelofibrosis seem to improve with INCB018424 therapy and correlate with symptom improvement. 50 Other drugs currently being tested include TG101348, a selective JAK2 inhibitor (TarGen, San
Francisco, CA) 47 ; XL019, a selective JAK2 inhibitor (Exelexis, San Francisco, CA) 46 ;
CEP-701, a tyrosine kinase inhibitor of JAK2 and FLT3 (Cephalon, Frazer, PA, USA) 45 ;
and ITF2357, a histone deacetylase inhibitor (Italfarmaco, Italy). 48 With each agent, preliminary results also report improvements in splenomegaly and symptoms in MF patients (Table 4) , although various toxicities seen (i.e., gastrointestinal, neuropathy
[XL019]) all share the potential for causing anemia and/or thrombocytopenia. To date, no JAK2 inhibitor has reported a significant ability to improve cytopenias, fibrosis, or histologic changes associated with MF. It should be mentioned that the trials mentioned a Risk factors for primary myelofibrosis (present at diagnosis):1) age >65 years, 2) hemoglobin <10 g/dL , 3) leukocytes >25 x 10 9 /L, 4) peripheral blood blasts ≥ 1%, 5) constitutional symptoms (weight loss >10%, night sweats or fevers) 
